A Phase 1/2 Study of REGN5093 M114 (METxMET Antibody Drug Conjugate) in Patients with MET Overexpressing Advanced Cancer
For more information about the trial above please contact the study team:
Principal Investigator, Mariam Alexander, at firstname.lastname@example.org.
Study Coordinator, Taryn Wheeler, at email@example.com.
Trial opened at the following institutions: Medical University of South Carolina